News

Ulta Beauty would like to put a couple of ugly quarters behind it. Wall Street still fancies the stock.

Bath & Body Works (BBWI) shares jumped Wednesday as the company raised its full-year earnings outloo

Organic sales returned to growth with margin expansion and strong earnings.

Estée Lauder’s second quarter showed a return to top-line growth, as sales outpaced Wall Street expectations and the market responded with strong optimism. Management attributed this performance to broad-based organic sales gains across every region and most product categories, notably in Skin Care and Fragrance, as well as operational improvements that lifted margins. CEO Stephane de la Faverie credited the company’s “streamlined organization and faster innovation launches,” while highlighting

In August 2026, The Estée Lauder Companies reported fourth-quarter sales of US$3,627 million and a quarterly net loss of US$116 million, alongside full-year sales of US$15.05 billion and net income of US$182 million, issued EPS guidance of US$2.52–US$2.85 for the year ending June 30, 2027, and affirmed a US$0.35 quarterly dividend payable on September 15, 2026. Separately, Estée Lauder’s research collaboration with the University of Leeds on color science and skin tone perception points to...

EL posts strong Q4 results as margin improvement, organic sales growth and broad regional gains support continued momentum into fiscal 2027.

Estee Lauder's (EL) turnaround continues to progress and its fiscal 2027 guidance is achievable, RBC

Este Lauder targets 3%-5% organic sales growth and a 12.7%-13.5% adjusted operating margin in fiscal 2027, with North America and Makeup in focus.

Organic sales rose 5% in Q4, the best quarter of fiscal 2026, as the company delivered a 66% surge in diluted EPS and outlined a confident fiscal 2027 outlook.

Moby summary of The Estée Lauder Companies Inc.'s Q4 2026 earnings call

Estee Lauder (EL) shares rallied Wednesday after the cosmetics maker bumped up its fiscal 2027 opera

EL beats fiscal fourth-quarter estimates as sales rise 6%, fueled by Skin Care and Fragrance growth and sharply higher operating income.

On this episode of Stock Movers: - Shares of Moderna (MRNA) surged by a record 101% - the stock's biggest intraday gain on record - after the biotech said a personalized cancer vaccine combined with partner Merck & Co.'s Keytruda helped cut the recurrence of melanoma in a large, late-stage trial. The study also met a key secondary goal of showing the shot could help prevent tumors from spreading to new areas of the body, the companies said in a statement Wednesday. - Shares of Estee Lauder (EL) rallied after the beauty company's adjusted earnings per share and sales metrics topped consensus expectations for the fourth quarter. The midpoint of fiscal 2027 organic sales and adjusted EPS guidance ranges are above Street views. - Shares of La-Z-Boy (LZB) tumbled at the open after the furniture maker's forecast sales for the second quarter missed the average analyst estimate.

Q2 retail earnings continue, Moderna sees positive Phase 3 results, and the Treasury lowers the longer-term bond rate.

Estee Lauder Companies Inc (NYSE:EL, XETRA:ELAA) shares jumped more than 15% on Wednesday after the beauty group posted fourth-quarter results that beat Wall Street estimates and raised its profit margin outlook for fiscal 2027. The company reported revenue of $3.6 billion for its fiscal...

Estee Lauder Companies (NYSE:EL) said fiscal 2026 marked a return to growth and a substantial improvement in profitability as the prestige beauty company advanced its Beauty Reimagined strategy and Profit Recovery and Growth Plan. For the full fiscal year, reported sales rose 5% and organic sales i

Although the revenue and EPS for Estee Lauder (EL) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Shares of Estée Lauder advanced on Wednesday as the beauty and cosmetics giant’s better-than-expected quarterly earnings showed Wall Street its growth plan is well underway. The company announced adjusted earnings of 39 cents a share in the fiscal fourth quarter, up from 9 cents a year ago and above Wall Street’s expectation of 32 cents. Estée Lauder reported adjusted earnings of $2.51 a share for the full fiscal year, up from $1.51 last year.

The cosmetics company forecast fiscal 2027 adjusted EPS of $3.10 to $3.35, with the midpoint above analyst estimates

Estee Lauder (EL) delivered earnings and revenue surprises of +21.88% and +2.15%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Retail earnings are set to offer a check of consumer health this week as the second quarter earnings season winds down.

Retail earnings are set to offer a check of consumer health this week as the second quarter earnings season winds down.

Retail earnings are set to offer a check of consumer health this week as the second quarter earnings season winds down.

Retail earnings are set to offer a check of consumer health this week as the second quarter earnings season winds down.

Beauty products company Estée Lauder (NYSE:EL) will be announcing earnings results this Wednesday before the bell. Here’s what to expect.

Estee Lauder (EL) is likely to provide full-year guidance in line with its preliminary expectations,

Barfresh Food Group (BRFH) delivered earnings and revenue surprises of -140.00% and -12.10%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Beyond analysts' top-and-bottom-line estimates for Estee Lauder (EL), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.

EL's fiscal fourth-quarter results are likely to benefit from fragrance momentum, key international markets and improving retail trends despite cost pressures.

ELF's 18.8% weekly surge is backed by Rhode growth, stronger guidance and global expansion, though core softness and a premium valuation raise execution stakes.